MHA Monday Report Feb. 5, 2024

MHA Monday Report

Registration Open for 2024 Healthcare Leadership Academy

Registration is open for the popular MHA Healthcare Leadership Academy program scheduled for March 13-15 and May 1-2. Delivered in partnership with Executive Core and Grand Valley State University for the past 11 years, two …


MDHHS Issues RFP for Peer Navigator Pilot Project

The Michigan Department for Health and Human Services (MDHHS) issued a Request for Proposal (RFP) to enhance support for pregnant and postpartum individuals facing substance use disorder. The Peer Navigator Pilot Project aims to …


Michigan State Loan Repayment Program Application Period Opens

The Michigan State Loan Repayment Program is now accepting applications through April 30. MSLRP assists employers in attracting and retaining medical, dental and mental healthcare providers in underserved communities by providing loan repayment. Healthcare …


Paxlovid Emergency Use Authorization Ends March 8

The U.S. Food and Drug Administration updated the Paxlovid Emergency Use Authorization, allowing Paxlovid that is currently in U.S. distribution to remain authorized for use through the labeled or extended expiration date, or …


MDHHS Release Medicaid Reimbursement Proposed Policy

The Michigan Department of Health and Human Services (MDHHS) recently released a proposed policy to establish additional Medicaid reimbursement for certain medically necessary drugs and therapeutics when provided in the inpatient hospital setting. The policy, …


SAMHSA Issues Final Rule on OUD Treatment

The Substance Abuse and Mental Health Services Administration (SAMHSA) issued a final rule Jan. 31 updating regulations for Opioid Treatment Programs and standards for treatment of opioid use disorder (OUD). These rules make permanent …


The Keckley Report

Paul KeckleyThe Three In-bound Truth Bombs set to Explode in U.S. Healthcare

“Truth bombs are falling in U.S. healthcare. They’re well-documented and financed. They take no prisoners and exact mass casualties.

Most healthcare organizations default to comfortable defenses. That’s not enough. Cyberwarfare, precision-guided drones and dirty bombs require a modernized defense. Lacking that, the system will be a commoditized public utility for most in 15 years.”

Paul Keckley, Jan. 29, 2024


News to Know

  • MHA-member physician residents are encouraged to save the date for GME Capitol Day, scheduled from 8:30 a.m. to 3:30 p.m. Wednesday, May 1, at the MHA Capital Advocacy Center.
  • MHA-member communications professionals are encouraged to save the date for this year’s MHA Communications Retreat, scheduled from 8:30 a.m. to 4 p.m. Tuesday, May 7, at the Henry Center for Executive Development in Lansing.

Paxlovid Emergency Use Authorization Ends March 8

The U.S. Food and Drug Administration (FDA) updated the Paxlovid Emergency Use Authorization (EUA), allowing Paxlovid that is currently in U.S. distribution to remain authorized for use through the labeled or extended expiration date, or until March 8, 2024, whichever comes first. EUA-labeled Paxlovid will no longer be authorized for emergency use after March 8.

The Paxlovid EUA will continue to authorize emergency use of Paxlovid manufactured and labeled in accordance with New Drug Application (NDA-labeled Paxlovid) for treating mild-to-moderate COVID-19 in high-risk pediatric patients (12 years of age and older) who are at high risk for progression to severe COVID-19.

Pharmacies may continue to dispense unexpired EUA-labeled Paxlovid through March 8. Any expired EUA-labeled Paxlovid and/or unused EUA-labeled Paxlovid remaining after March 8, must be returned to the manufacturer, or disposed of in accordance with federal, state and local regulations.

Patients with Paxlovid prescriptions will receive either EUA-labeled or NDA-labeled Paxlovid until March 8. After that, patients will receive NDA-labeled Paxlovid. More information about the difference in packaging between EUA-labeled and NDA-labeled Paxlovid is available on the FDA website.

Eligible patients can receive free Paxlovid through the PAXCESS Program until Dec. 31, 2024.

Members with questions  may contact Kelsey Ostergren at the MHA.